Colchicine Therapy Guidelines

Pre-Treatment Evaluation

The American College of Rheumatology recommends obtaining baseline complete blood count, liver enzymes, creatinine phosphokinase, and renal function tests before initiating colchicine therapy for dermatological conditions 1
Baseline liver function tests, including AST and ALT, should be assessed to evaluate hepatic function before starting colchicine, as recommended by the European League Against Rheumatism 2
Creatine phosphokinase levels should be measured at baseline to detect any muscle enzyme elevation, according to the American College of Rheumatology 2
Renal function assessment, including serum creatinine and calculated creatinine clearance, is essential before initiating colchicine therapy, as advised by the European League Against Rheumatism 1
Urinalysis should be performed to screen for proteinuria, particularly in patients considering long-term colchicine therapy, as recommended by the American College of Rheumatology 1

The European League Against Rheumatism warns against concomitant use of colchicine with strong CYP3A4 inhibitors, such as macrolides, azole antifungals, protease inhibitors, verapamil, cyclosporine, and statins, due to increased risk of toxicity 3
Patients should be screened for medications that interact with colchicine via cytochrome P450 3A4 or P-glycoprotein pathways to minimize the risk of fatal toxicity, as recommended by the American College of Rheumatology 3

The American College of Rheumatology recommends monitoring response, toxicity, and compliance every 6 months with repeat complete blood count, liver enzymes, creatinine phosphokinase, and renal function tests during colchicine therapy 2
Regular monitoring schedule should include every 6 months minimum: complete blood count, liver enzymes, creatinine phosphokinase, and renal function tests, as advised by the European League Against Rheumatism 2
Urinalysis should be performed at least yearly, and more frequently if the disease is poorly controlled, according to the American College of Rheumatology 1
More frequent monitoring (every 3 months) is recommended during dose escalation or in patients with active disease, as recommended by the European League Against Rheumatism 5

Patients with renal impairment (CrCl <50 mL/min) should be closely monitored for signs of colchicine toxicity, including diarrhea, progressive muscle weakness, elevated creatinine phosphokinase, acute worsening of renal function, cytopenias, and neuropathy, as advised by the American College of Rheumatology 2
If liver enzymes exceed 2-fold the upper limit of normal, the colchicine dose should be reduced, and the cause should be investigated further, according to the European League Against Rheumatism 2

Patients should be monitored for early manifestations of toxicity, including gastrointestinal symptoms (abdominal cramping, vomiting, diarrhea), neuromuscular toxicity (progressive muscle weakness, elevated creatinine phosphokinase), hematologic toxicity (cytopenias, bone marrow suppression), and multiorgan failure, as recommended by the American College of Rheumatology 3
Gastrointestinal symptoms, such as abdominal cramping, vomiting, and diarrhea, may herald serious toxicity requiring immediate discontinuation, according to the European League Against Rheumatism 7

Colchicine should be discontinued immediately if signs of toxicity develop, including progressive muscle weakness, elevated creatinine phosphokinase, cytopenias, neuropathy, or acute worsening of renal function, as recommended by the American College of Rheumatology 1
Specific stopping criteria include immediate discontinuation for any signs of colchicine toxicity, severe gastrointestinal intolerance despite dose adjustment, and development of contraindications, such as severe renal failure (CrCl <10 mL/min) without dialysis, as advised by the European League Against Rheumatism 1

For dermatological conditions, treatment duration depends on disease activity and response, and there is no standardized duration for most cutaneous disorders, according to the American College of Rheumatology 3
If a patient achieves stable remission with no disease activity for more than 5 years and no elevated acute phase reactants, dose reduction could be considered after expert consultation with continued monitoring, as recommended by the European League Against Rheumatism 3

Dose reduction should be gradual, by no more than 0.5 mg per occasion, with a wait of 6 months between dose reductions, as advised by the American College of Rheumatology 7
Acute phase reactants (CRP or SAA) should be monitored 3 months after each reduction, and urinary protein monitoring should be continued, according to the European League Against Rheumatism 7

Combining colchicine with strong CYP3A4 inhibitors in patients with renal or hepatic impairment is contraindicated and can be fatal, as warned by the American College of Rheumatology 1
Gastrointestinal symptoms should not be assumed to be benign, as they may herald serious toxicity requiring immediate discontinuation, according to the European League Against Rheumatism 3
Colchicine should not be discontinued during pregnancy, as current evidence supports safety during conception, pregnancy, and lactation, as recommended by the American College of Rheumatology 2